Skip to main content
. 2011 Aug 16;36(6):843–854. doi: 10.1038/ijo.2011.158

Figure 1.

Figure 1

Study design. *From 20–52 weeks, participants/investigators remained blinded to liraglutide/placebo treatment but the sponsor was unblinded; after 1 year, all were unblinded.